Abstract
The efffect of Cevimeline (SNI-2011), a novel muscarinic receptor agonist, that is, (± ) -cis-2-methylspilo [1, 3-oxathiolane-5, 3'-quinuclidine] hydrochloride hemihydrate, on salivary secretion was studied in streptozotocin (STZ) -induced diabetic mice. Three weeks after induction of diabetes, saliva flow, protein secretion, and amylase activity were measured. Saliva was collected from the oral cavity at intervals of 5 min, over 20 min, following injection of 10mg/kg of Cevimeline.
Single intraperitoneal injection of Cevimeline stimulated salivary flow in the STZ diabetic mice. However, the volume was significantly decreased compared with the control mice, approximately half of the control mice. Protein concentration in the secreted saliva was increased in the diabetic mice group compared with the control mice group. In amylase activity, when the activity was indicated as unit/mL, a single injection of Cevimeline induced a significantly high value in the diabetic mice. However, the total amylase secretion over 20 min tended to decrease in the diabetic mice, despite that the total salivary protein secretion over 20 min was increased.
This study demonstrated the effects of single administration of Cevimeline in STZinduced diabetic mice, and suggested usefulness for patients with salivary gland dysfunction.
